

PhotoPill Medical Launches Clinical Study for Novel IBD-Cap capsule with Crohn's Disease Patients

PhotoPill Medical's Crohn's Disease study is now Actively Recruiting Participants for Groundbreaking Study on Inflammatory Bowel Disease (IBD)

REHOVOT, ISRAEL, May 28, 2025 /EINPresswire.com/ -- [PhotoPill Medical](#), a leader in innovative

“

Crohn's is a condition that requires constant management and treatment, the IBD-Cap aims to significantly improve patient's quality of life by delivering a much safer, medication-free treatment”

Sharon Ben Yehuda

therapeutic solutions for gastrointestinal diseases, announced today the initiation of the second part and the enrolment of the first patient, of a clinical study for its revolutionary IBD-Cap capsule, a novel non-pharmaceutical technology developed for the treatment of Crohn's disease flare-ups. After successfully completing the safety part of the study - the study is now open and actively recruiting patients diagnosed with Crohn's disease.

The IBD-Cap capsule represents a next-generation approach for managing inflammatory bowel diseases. Designed as a swallowable capsule, the IBD-Cap combines

advanced technology and algorithms for delivering Photo-Bio-Modulation treatment (light) directly to the inflamed area within the intestine, with no medications or chemicals and with no expected side-effects.

“Crohn's disease is a lifelong condition that requires constant management and treatment, and our IBD-Cap aims to significantly improve patient's quality of life while delivering a much safer, medication-free treatment,” says Sharon Ben Yehuda, VP Clinical Research & Development at PhotoPill Medical. “This clinical study is a crucial step toward validating our technology and bringing it to the patients who need it most.”

The prospective study will evaluate the safety and effectiveness, of the IBD-Cap capsule in adults with mild-to-moderate small bowel Crohn's disease. Participants will be monitored throughout the study period and their disease condition and feedback will be recorded to assess capsule performance.

Study Highlights:

- Currently enrolling adults diagnosed with mild-to-moderate Crohn's disease
- Participation includes use of the IBD-Cap capsule along with standard care assessments
- Conducted at leading gastroenterology centers across Israel
- Designed to gather data on capsule safety, effectiveness, and patient outcomes

Patients, caregivers, and healthcare providers interested in learning more or participating in the study can contact sharon@photopill-med.com.

About PhotoPill Medical

PhotoPill Medical is a medical technology company dedicated to transforming gastrointestinal therapy through non-pharmaceutical, patient-centered innovations. With a mission to improve quality of life and disease condition for patients living with chronic GI diseases, PhotoPill Medical is developing a portfolio of smart treatment tools designed to empower clinicians and patients alike.

Ram Ben Yehuda

PhotoPill Medical

+972 50-562-6404

[email us here](#)



IBD-Cap

This press release can be viewed online at: <https://www.einpresswire.com/article/816486354>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.